Results 131 to 140 of about 2,638,293 (327)
Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes +17 morewiley +1 more sourcePATHOLOGY [PDF]
Neuro-Oncology, 1992 J.-i. Adachi, K. Totake, M. Shirahata, K. Mishima, T. Suzuki, T. Yanagisawa, K. Fukuoka, R. Nishikawa, A. Arimappamagan, N. Manoj, A. Mahadevan, D. Bhat, H. Arvinda, B. Indiradevi, S. Somanna, B. Chandramouli, S. A. Petterson, S. K. Hermansen, R. H. Dahlrot, S. Hansen, B. W. Kristensen, F. Carvalho, S. Jalali, S. Singh, S. Croul, K. Aldape, G. Zadeh, J. Choi, S.-H. Park, S. K. Khang, Y.-L. Suh, S. P. Kim, Y. S. Lee, S. H. Kim, S. Coberly, K. Samayoa, Y. Liu, P. Kiaei, J. Hill, S. Patterson, M. Damore, S. Dahiya, R. Emnett, J. Phillips, D. Haydon, J. Leonard, A. Perry, D. Gutmann, S. Epari, S. Ahmed, M. Gurav, S. Raikar, A. Moiyadi, P. Shetty, T. Gupta, R. Jalali, J. Georges, A. Zehri, E. Carlson, N. Martirosyan, A. Elhadi, J. Nichols, L. Ighaffari, J. Eschbacher, B. Feuerstein, T. Anderson, M. Preul, K. Jensen, P. Nakaji, H. Girardi, F. Monville, S. Carpentier, M. Giry, J. Voss, R. Jenkins, B. Boisselier, V. Frayssinet, C. Poggionovo, A. Catteau, K. Mokhtari, M. Sanson, H. Peyro-Saint-Paul, C. Giannini, T. Hide, H. Nakamura, K. Makino, S. Yano, S. Anai, N. Shinojima, J.-i. Kuroda, T. Takezaki, J.-i. Kuratsu, F. Higuchi, H. Matsuda, K. Iwata, K. Ueki, P. Kim, J. Kong, L. Cooper, F. Wang, J. Gao, G. Teodoro, L. Scarpace, T. Mikkelsen, M. Schniederjan, C. Moreno, J. Saltz, D. Brat, U. Cho, Y.-K. Hong, Y. S. Lee, R. Lober, L. Lu, M. H. Gephart, P. Fisher, M. Miyazaki, H. Nishihara, T. Itoh, M. Kato, S. Fujimoto, T. Kimura, M. Tanino, S. Tanaka, N. Nguyen, G. Moes, J. L. Villano, H. Nishihara, H. Kanno, Y. Kato, S. Tanaka, T. Ohnishi, H. Harada, S. Ohue, S. Kouno, A. Inoue, D. Yamashita, S. Okamoto, M. Nitta, Y. Muragaki, T. Maruyama, T. Sawada, T. Komori, T. Saito, Y. Okada, S. B. Omay, J. M. Gunel, V. E. Clark, J. Li, E. Z. E. Omay, A. Serin, L. E. Kolb, R. M. Hebert, K. Bilguvar, K. Ozduman, M. N. Pamir, T. Kilic, J. Baehring, J. M. Piepmeier, C. W. Brennan, J. Huse, P. H. Gutin, K. Yasuno, A. Vortmeyer, M. Gunel, A. Perry, S. Pugh, C. L. Rogers, D. Brachman, W. McMillan, J. Jenrette, I. Barani, D. Shrieve, A. Sloan, M. Mehta, A. Prabowo, A. Iyer, T. Veersema, J. Anink, A. S.-v. Meeteren, W. Spliet, P. van Rijen, T. Ferrier, D. Capper, M. Thom, E. Aronica, T. Chharchhodawala, M. Sable, M. C. Sharma, C. Sarkar, V. Suri, M. Singh, V. Santosh, B. Thota, M. Srividya, K. Sravani, S. Shwetha, A. Arivazhagan, K. Thennarasu, B. Chandramouli, A. Hegde +199 moreopenaire +2 more sourcesAberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu +12 morewiley +1 more sourceSIU-ICUD: Localized Prostate Cancer: Pathological Factors That Influence Outcomes and Management
Société Internationale d’Urologie JournalBackground/Objectives: Pathological factors are integral in the risk stratification and management of localized prostate cancer. In recent years, there has been an upsurge of studies that uncovered novel approaches and have refined prognostic factors for Gladell P. Paner, Eva M. Compérat, Samson W. Fine, James G. Kench, Glen Kristiansen, Rajal B. Shah, Steven Christopher Smith, John R. Srigley, Geert J. L. H. van Leenders, Murali Varma, Ming Zhou, Mahul B. Amin +11 moredoaj +1 more sourceClinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline
Diabetes, Metabolic Syndrome and Obesity, 2022 Chunmei Qin,1– 3 Yiting Wang,1,2 Lijun Zhao,1,2 Junlin Zhang,1,2 Honghong Ren,1,2 Yutong Zou,1,2 Yucheng Wu,1,2 Tingli Wang,1,2 Yuancheng Zhao,1,2 Rui Zhang,1,2 Huan Xu,4 Jie Zhang,5 Mark E Cooper,6 Fang Liu1,2 1Division of Nephrology, West China ...Qin C, Wang Y, Zhao L, Zhang J, Ren H, Zou Y, Wu Y, Wang T, Zhao Y, Zhang R, Xu H, Zhang J, Cooper ME, Liu F +13 moredoaj Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles
Molecular Oncology, EarlyView.Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea +9 morewiley +1 more source
